Pain · children and adolescents with juvenile dermatomyositis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Fatigue · children and adolescents with juvenile dermatomyositis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · children and adolescents with juvenile dermatomyositis
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Muscle strength · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Aerobic capacity · people with facioscapulohumeral muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time from birth until death or full‐time ventilation · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen probably leads to lower time from birth until death or full‐time ventilationa compared with sham procedure (moderate certainty).
1 finding from 1 review
Acquisition of the ability to sit · children with SMA type I
1 finding from 1 review
Acquisition of the ability to stand · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in motor score after two years · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events attributable to treatment · children with SMA type I
1 finding from 1 review
Severe adverse events attributable to treatment · children with SMA type I
1 finding from 1 review
Acquisition of head control · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen probably leads to higher acquisition of head control within one year after the onset of… compared with sham procedure (moderate certainty).
1 finding from 1 review
Acquisition of the ability to sit · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen showed no clear difference in acquisition of the ability to sit within one year after the onset of… compared with sham procedure (moderate certainty).
1 finding from 1 review
Acquisition of the ability to stand · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen showed no clear difference in acquisition of the ability to stand within one year after the onset… compared with sham procedure (moderate certainty).
1 finding from 1 review
Change in motor score after one year · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen probably leads to higher change in motor disability score ‐ response on HINE‐2 within one… compared with sham procedure (moderate certainty).
1 finding from 1 review
Adverse events attributable to treatment · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen showed no clear difference in adverse events attributable to treatment Measured as adverse events… compared with sham procedure (moderate certainty).
1 finding from 1 review
Severe adverse events attributable to treatment Measured as severe adverse events (all) · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen probably leads to lower severe adverse events attributable to treatment Measured as severe… compared with sham procedure (moderate certainty).
1 finding from 1 review
Time from birth until death or full‐time ventilation · children with SMA type I
1 finding from 1 review
Acquisition of head control · children with SMA type I
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
In‐hospital death from any cause occurring within 4 weeks of randomization or the beginning of treatment · individuals with infant botulism
1 finding from 1 review